Evidence map›Paper›PMID 27762326›Full record

ArticleScientific reports2016

Imaging hydrogen peroxide in Alzheimer's disease via cascade signal amplification.

Jian Yang, Jing Yang, Steven H Liang, Yungen Xu, Anna Moore, Chongzhao Ran

Abstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Microglia-targetedMaterials today. Bio · 2026
    Article
  3. Article
  4. Article
  5. AlClFrontiers in toxicology · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Neuroprotective effects ofFood science & nutrition · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jian YangMolecular Imaging Laboratory, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 01890, USA.
Jing YangMolecular Imaging Laboratory, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 01890, USA.
Steven H LiangDivision of Nuclear Medicine and Molecular Imaging &Center for Advanced Medical Imaging Sciences, Massachusetts General Hospital and Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA.
Yungen XuSchool of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Anna MooreMolecular Imaging Laboratory, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 01890, USA.
Chongzhao RanMolecular Imaging Laboratory, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 01890, USA.

Funding

New PET tracers for neuroimaging of FAAH in endocannabinoid signalingK01DA038000 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2014 to 2018
$927k
Imaging AD Amyloidosis Pathology by Novel Multi-modal NIR/PET/19F MRI ProbesK25AG036760 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI RAN, CHONGZHAO · 2010 to 2014
$770k
500 MHz NMR Spectrometer for Molecular Imaging ApplicationsS10RR023385 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2007 to 2007
$500k
Double-blocking Anti-crosslinking Strategy for AD Drug DevelopmentR21AG050158 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI RAN, CHONGZHAO · 2015 to 2016
$475k
IVIS Spectrum Imaging SystemS10RR025504 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI MOORE, ANNA · 2009 to 2009
$341k
Near-infrared molecular imaging for monitoring therapy in AD mouse modelsR03AG050038 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI RAN, CHONGZHAO · 2015 to 2016
$171k
NCRR NIH HHS S10 RR023385NCRR NIH HHS S10 RR025504NIA NIH HHS K25 AG036760NIA NIH HHS R03 AG050038NIA NIH HHS R21 AG050158NIDA NIH HHS K01 DA038000
6 · The paper itself

Abstract

In brains of Alzheimer's disease (AD), reactive oxygen species (ROS) levels are significantly higher than that of healthy brains. Evidence suggests that, during AD onset and progression, a vicious cycle revolves around amyloid beta (Aβ) production, aggregation, plaque formation, microglia/immunological responses, inflammation, and ROS production. In this cycle, ROS species play a central role, and H

Indexed as

Brain ChemistryAlzheimer DiseaseAnimalsDisease Models, AnimalFluorescent DyesHydrogen PeroxideMiceOptical ImagingFluorescent DyesHydrogen Peroxide

Identifiers

PMID27762326
PMCPMC5071891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.